In acute kidney injury and chronic kidney disease, de novo NAD+ biosynthesis is impaired, and substantial decreases in the levels of NAD+ can reduce energy generation. More recently, NAD+ augmentation through supplementation with nicotinamide mononucleotide (NMN) or nicotinamide (NAM), an NAD+ precursor, has been proposed as for the prevention of numerous kidney illnesses, including AKI, CKD, the AKI-to-CKD transition, and diabetic nephropathy. Our experimental results showed that NAD+ lowered TGF-β1-induced extracellular matrix deposition in kidney organoids produced from hiPSCs, confirming its therapeutic efficacy in chronic kidney disease....In conclusion, activation of Insig1 in PTCs markedly attenuated CKD, possibly by maintaining NAD+ homeostasis and controlling ER expansion via the transcriptional repression of Aldh1a1 in PTCs.